Rozlytrek Third FDA-Approved Tumor-Agnostic Drug and Second Treatment for Patients with NTRK Fusion Tumors

Web Exclusives - FDA Updates

On August 15, 2019, the FDA accelerated the approval of entrectinib (Rozlytrek; Genentech), an oral kinase inhibitor, for the treatment of adults and adolescents whose cancer involves neurotrophic tyrosine receptor kinase (NTRK) gene fusion that has no effective treatments. The FDA granted entrectinib a priority review and breakthrough therapy and orphan drug designations. This is the third cancer drug approved by the FDA based on a common biomarker and the second drug for patients with NTRK gene fusion.

“We’re seeing continued advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine,” said FDA Acting Commissioner Ned Sharpless, MD. “Today’s approval includes an indication for pediatric patients, 12 years of age and older, who have NTRK fusion–positive tumors by relying on efficacy information obtained primarily in adults,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

On the same day, the FDA also approved entrectinib for the treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and a ROS1 mutation.

Entrectinib was evaluated in 4 clinical trials with 54 adults with NTRK fusion–positive tumors. The overall response rate (ORR) was 57%, including 7.4% complete responses, with entrectinib. Of the 31 patients with overall response, 61% had responses lasting 9 months or longer. The most common cancer locations were the lung, salivary gland, breast, thyroid, and colon/rectum.

The clinical trials also included 51 adults with ROS1-positive lung cancer. The ORR for those patients was 78%, including 5.9% complete responses. Among the 40 patients with NSCLC whose tumor responded to treatment with entrectinib, 55% had responses lasting 12 months or longer.

The most common side effects with entrectinib were fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, dysesthesia, dyspnea, myalgia, cognitive impairment, weight gain, cough, vomiting, fever, arthralgia, and vision disorders. The most serious side effects were congestive heart failure, central nervous system effects, skeletal fractures, hepatotoxicity, hyperuricemia, QT prolongation, and vision disorders.

Related Items
November 11, 2019 — Oncology News & Updates
Web Exclusives published on November 11, 2019 in FDA Updates, In the News
FDA News
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in FDA Updates
Nubeqa New Oral Therapy FDA Approved for Nonmetastatic Prostate Cancer
Web Exclusives published on October 29, 2019 in FDA Updates
Turalio First FDA-Approved Systemic Therapy for Tenosynovial Giant-Cell Tumor
Web Exclusives published on October 29, 2019 in FDA Updates
October 28, 2019 – Oncology News & Updates
Web Exclusives published on October 28, 2019 in FDA Updates, In the News, Ovarian Cancer
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
FDA on In Vitro Diagnostics, Vaping; Cost of Novel Treatments
Web Exclusives published on October 15, 2019 in FDA Updates, In the News, NCCN
Darzalex Combination Receives Approval for First-Line Treatment of Patients with Multiple Myeloma Eligible for Transplant
Web Exclusives published on September 30, 2019 in FDA Updates, In the News, Multiple Myeloma
FDA News
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in FDA Updates
Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer
Yvette Florio Lane
Web Exclusives published on June 26, 2019 in FDA Updates, In the News
Last modified: October 29, 2019